Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490535 | 0.88 | TLR7 (0.61) | TLR7TLR8NUDT1 | |
| SCHEMBL1490849 | 0.87 | TLR7 (0.48) | TLR7TLR8NUDT1 | |
| SCHEMBL1490462 | 0.86 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL1490818 | 0.85 | TLR7 (0.45) | TLR7TLR8NUDT1 | |
| SCHEMBL1753621 | 0.84 | TLR7 (0.53) | TLR7TLR8NUDT1 | |
| SCHEMBL1490747 | 0.83 | TLR7 (0.43) | TLR7TLR8NUDT1 | |
| SCHEMBL1490882 | 0.83 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL12756979 | 0.79 | TLR7 (0.42) | TLR7TLR8NUDT1 | |
| SCHEMBL1490871 | 0.79 | TLR7 (0.61) | TLR7TLR8NUDT1 | |
| SCHEMBL1490775 | 0.78 | EGLN1 (0.44) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897609-B2 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897609-B2 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897609-B2 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| WO-2006038923-A2 | ARYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | IL2, IRF3, EIF2AK2 | TLR7 85/4885TLR8 161/4885NUDT1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.